Bio-Techne's gross profit for the
three
months ended in Mar. 2024 was $205 Mil. Bio-Techne's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $771 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Bio-Techne's gross profit for the
three
months ended in Mar. 2024 was $205 Mil. Bio-Techne's Revenue for the
three
months ended in Mar. 2024 was $303 Mil. Therefore, Bio-Techne's Gross Margin % for the quarter that ended in Mar. 2024 was 67.43%.
Bio-Techne had a gross margin of 67.43% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Bio-Techne was 70.27%. The lowest was 65.41%. And the median was 67.59%.
Bio-Techne Gross Profit Historical Data
The historical data trend for Bio-Techne's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Techne's Gross Profit
For the Biotechnology subindustry, Bio-Techne's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Gross Profit distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Gross Profit falls into.
Bio-Techne Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Bio-Techne's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $771 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio-Techne (NAS:TECH) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio-Techne had a gross margin of 67.43% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Bio-Techne Gross Profit Related Terms
Thank you for viewing the detailed overview of Bio-Techne's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 